UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Pujadas ER
(2023)
Prediction of incident cardiovascular events using machine learning and CMR radiomics.
in European radiology
Pulit SL
(2019)
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
in Human molecular genetics
Puyol-Antón E
(2022)
A multimodal deep learning model for cardiac resynchronisation therapy response prediction.
in Medical image analysis
Puyol-Antón E
(2022)
Fairness in Cardiac Magnetic Resonance Imaging: Assessing Sex and Racial Bias in Deep Learning-Based Segmentation
in Frontiers in Cardiovascular Medicine
Pyrkov TV
(2018)
Quantitative characterization of biological age and frailty based on locomotor activity records.
in Aging
Pärna K
(2022)
A Principal Component Informed Approach to Address Polygenic Risk Score Transferability Across European Cohorts
in Frontiers in Genetics
Pölsterl S
(2023)
Identification of causal effects of neuroanatomy on cognitive decline requires modeling unobserved confounders.
in Alzheimer's & dementia : the journal of the Alzheimer's Association
Qi G
(2022)
Genome-wide association studies of 27 accelerometry-derived physical activity measurements identified novel loci and genetic mechanisms.
in Genetic epidemiology
Qi S
(2022)
Derivation and utility of schizophrenia polygenic risk associated multimodal MRI frontotemporal network.
in Nature communications
Qi X
(2022)
Index of multiple deprivation contributed to common psychiatric disorders: A systematic review and comprehensive analysis.
in Neuroscience and biobehavioral reviews
Qi X
(2021)
Sex specific effect of gut microbiota on the risk of psychiatric disorders: A Mendelian randomisation study and PRS analysis using UK Biobank cohort.
in The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
Qian J
(2022)
LARGE-SCALE MULTIVARIATE SPARSE REGRESSION WITH APPLICATIONS TO UK BIOBANK.
in The annals of applied statistics
Qian Q
(2022)
Physical activity and risk of gallstone disease: A Mendelian randomization study.
in Frontiers in genetics
Qian Y
(2021)
Observational and genetic evidence highlight the association of human sleep behaviors with the incidence of fracture.
in Communications biology
Qiao Y
(2022)
Role of depression in the development of cardiometabolic multimorbidity: Findings from the UK Biobank study.
in Journal of affective disorders
Qiao Z
(2023)
Estimation and implications of the genetic architecture of fasting and non-fasting blood glucose.
in Nature communications
Qin X
(2022)
Assessing the effect of interaction between gut microbiome and inflammatory bowel disease on the risks of depression.
in Brain, behavior, & immunity - health
Qiu J
(2022)
Iron status and mental disorders: A Mendelian randomization study.
in Frontiers in nutrition
Qiu K
(2022)
Gender-specific association between obstructive sleep apnea and cognitive impairment among adults.
in Sleep medicine
Qiu W
(2022)
Interpretable machine learning prediction of all-cause mortality.
in Communications medicine
Quach BC
(2020)
Expanding the genetic architecture of nicotine dependence and its shared genetics with multiple traits.
in Nature communications
Quester J
(2022)
Endogenous DHEAS Is Causally Linked With Lumbar Spine Bone Mineral Density and Forearm Fractures in Women.
in The Journal of clinical endocrinology and metabolism
Quick C
(2020)
Integrating comprehensive functional annotations to boost power and accuracy in gene-based association analysis.
in PLoS genetics
Quick C
(2019)
emeraLD: rapid linkage disequilibrium estimation with massive datasets.
in Bioinformatics (Oxford, England)
Quintero Reis A
(2023)
Functional and molecular characterization of suicidality factors using phenotypic and genome-wide data.
in Molecular psychiatry
Quintero Santofimio V
(2022)
P189 Small airways obstruction and lifetime occupational exposure in the UK Biobank cohort
Rae W
(2022)
Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations.
in Science immunology
Rafipoor H
(2022)
Identifying microstructural changes in diffusion MRI; How to circumvent parameter degeneracy.
in NeuroImage
Raghupathy N
(2022)
AB0003 PHENOTYPIC EFFECTS OF GENETIC LOSS OF FUNCTION IN TYROSINE KINASE 2 USING LARGE-SCALE BIOBANKS
in Annals of the Rheumatic Diseases
Rahman MS
(2021)
Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain.
in Annals of the rheumatic diseases
Raichlen D
(2022)
Leisure-time sedentary behaviors are differentially associated with all-cause dementia regardless of engagement in physical activity
in Proceedings of the National Academy of Sciences
Raichlen DA
(2020)
Differential associations of engagement in physical activity and estimated cardiorespiratory fitness with brain volume in middle-aged to older adults.
in Brain imaging and behavior
Raies A
(2022)
DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets.
in Communications biology
Raisi-Estabragh Z
(2020)
Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank.
in Journal of public health (Oxford, England)
Raisi-Estabragh Z
(2022)
Associations of cognitive performance with cardiovascular magnetic resonance phenotypes in the UK Biobank.
in European heart journal. Cardiovascular Imaging
Raisi-Estabragh Z
(2020)
Age, sex and disease-specific associations between resting heart rate and cardiovascular mortality in the UK BIOBANK.
in PloS one
Raisi-Estabragh Z
(2022)
Corrigendum to: Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study.
in European heart journal. Cardiovascular Imaging
Raisi-Estabragh Z
(2023)
Incident Clinical and Mortality Associations of Myocardial Native T1 in the UK Biobank.
in JACC. Cardiovascular imaging
Raisi-Estabragh Z
(2021)
Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK Biobank.
in Aging clinical and experimental research
Raisi-Estabragh Z
(2022)
Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank.
in Heart (British Cardiac Society)
Raisi-Estabragh Z
(2022)
Left atrial structure and function are associated with cardiovascular outcomes independent of left ventricular measures: a UK Biobank CMR study.
in European heart journal. Cardiovascular Imaging
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |